THU0110 The Effect of Subcutaneous (SC) Methotrexate (MTX) and Adalimumab (ADA) on Cytokine Profile in MTX-Naive Patients with Early Rheumatoid Arthritis (RA)
Objectives To evaluate the changes in cytokine profile in MTX-naive patients (pts) with early RA during MTX and ADA+MTX therapy Methods Serum samples from 45 MTX-naive adults with early RA who received MTX (35 woman, mean age 53,5; 46-59,5 years, mean disease duration 7,0; 4,0-11,5 months, mean DAS...
Gespeichert in:
| Veröffentlicht in: | Annals of the rheumatic diseases 2014-06, Vol.73 (Suppl 2), p.215-216 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 216 |
|---|---|
| container_issue | Suppl 2 |
| container_start_page | 215 |
| container_title | Annals of the rheumatic diseases |
| container_volume | 73 |
| creator | Avdeeva, A.S. Novikov, A.A. Aleksandrova, E.N. Karateev, D.E. Luchihina, E.L. Nasonov, E.L. |
| description | Objectives To evaluate the changes in cytokine profile in MTX-naive patients (pts) with early RA during MTX and ADA+MTX therapy Methods Serum samples from 45 MTX-naive adults with early RA who received MTX (35 woman, mean age 53,5; 46-59,5 years, mean disease duration 7,0; 4,0-11,5 months, mean DAS 28 5,8; 4,9-6,4, RF positive-91%, anti-CCP positive-96%) were analyzed for selected markers of inflammation. The levels of IL-1b, IL-1Pa, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12, IL-13, IL-15, IL-17, Eotaxin, FGF-basic, IFN-γ, IP-10, MCP-1, MIP-1α, MIP-1β, RANTES, TNF-α, VEGF (pg/ml) were tested by multiplex technology xMAP at baseline and weeks 12 and 24 Results After 3 months the efficacy of SC MTX have met the goal (EULAR response) in 23 (51%) of pts (not switching group). Switching to combination with ADA was required in 22 (49%) of pts (switching group). The relations between achievement of LDA or remission according to treatment regimens are shown in the table 1. Table 1 Weeks Parameters Not switching group (n=23) Switching group (n=22) Baseline DAS 28 4,9 (4,3–6,0) 6,1 (5,9–6,8)§ Week 12 DAS 28 3,5 (2,8–3,9)* 5,3 (5,6–5,9)*§ DAS 28 remission/LDA 34,8% 0 Week 24 DAS 28 2,9 (2,1–3,6)* 3,4 (3,2–4,4)* DAS 28 remission/LDA 60,9% 31,8% *p |
| doi_str_mv | 10.1136/annrheumdis-2014-eular.2698 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1777977940</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>4008700231</sourcerecordid><originalsourceid>FETCH-LOGICAL-b1270-16dc3535e63b27fa3d7801dd6f87d52ae0ca3fdcb7fe2c3a69e6d0aecfc5a35a3</originalsourceid><addsrcrecordid>eNqVkcFuEzEQhi0EEqHwDpZ6SQ5b7HXi3YjTKqQUqQXUphI3a3Y91jrs2sX2Arlx4T14Np4Eh3DgijTSaEbz_79GHyHnnF1wLuRLcC70OI3axqJkfFngNEC4KOW6fkRmfCnrvJbsMZkxxkSxXMvqKXkW4z6PrOb1jPzcXd0zztmv7z92PdKtMdgl6g29m9puSuDQT5HO7zYLeoOp9yngN0hI5ze7jwsKTtNGw2DHaYSWzpvXzYJ6RzeH5D9Zh_RD8MYOSK2jWVC8A_slLyFZdCnSrzb1dAthONDb4xuQvM2GIfXBJptjb5vFc_LEwBDxxd9-Ru4vt7vNVXH9_s3bTXNdtLysWMGl7sRKrFCKtqwMCF3VjGstTV3pVQnIOhBGd21lsOwEyDVKzQA7061A5Doj5yffh-A_TxiT2vspuBypeFVV61xLlq9ena664GMMaNRDsCOEg-JMHZGof5CoIxL1B4k6IslqeVK34_6_hL8BddGYkA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1777977940</pqid></control><display><type>article</type><title>THU0110 The Effect of Subcutaneous (SC) Methotrexate (MTX) and Adalimumab (ADA) on Cytokine Profile in MTX-Naive Patients with Early Rheumatoid Arthritis (RA)</title><source>BMJ Journals - NESLi2</source><creator>Avdeeva, A.S. ; Novikov, A.A. ; Aleksandrova, E.N. ; Karateev, D.E. ; Luchihina, E.L. ; Nasonov, E.L.</creator><creatorcontrib>Avdeeva, A.S. ; Novikov, A.A. ; Aleksandrova, E.N. ; Karateev, D.E. ; Luchihina, E.L. ; Nasonov, E.L.</creatorcontrib><description>Objectives To evaluate the changes in cytokine profile in MTX-naive patients (pts) with early RA during MTX and ADA+MTX therapy Methods Serum samples from 45 MTX-naive adults with early RA who received MTX (35 woman, mean age 53,5; 46-59,5 years, mean disease duration 7,0; 4,0-11,5 months, mean DAS 28 5,8; 4,9-6,4, RF positive-91%, anti-CCP positive-96%) were analyzed for selected markers of inflammation. The levels of IL-1b, IL-1Pa, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12, IL-13, IL-15, IL-17, Eotaxin, FGF-basic, IFN-γ, IP-10, MCP-1, MIP-1α, MIP-1β, RANTES, TNF-α, VEGF (pg/ml) were tested by multiplex technology xMAP at baseline and weeks 12 and 24 Results After 3 months the efficacy of SC MTX have met the goal (EULAR response) in 23 (51%) of pts (not switching group). Switching to combination with ADA was required in 22 (49%) of pts (switching group). The relations between achievement of LDA or remission according to treatment regimens are shown in the table 1. Table 1 Weeks Parameters Not switching group (n=23) Switching group (n=22) Baseline DAS 28 4,9 (4,3–6,0) 6,1 (5,9–6,8)§ Week 12 DAS 28 3,5 (2,8–3,9)* 5,3 (5,6–5,9)*§ DAS 28 remission/LDA 34,8% 0 Week 24 DAS 28 2,9 (2,1–3,6)* 3,4 (3,2–4,4)* DAS 28 remission/LDA 60,9% 31,8% *p<0,05 from baseline, §p<0,05 between the groups. In not-switching group MTX induced reduction in proinflammatory (IL-6, -17, TNF-α), anti-inflammatory (IL-4, -5, -9, -13) cytokines, chemokines (IP-10) and growth factors (FGF) at week 12; IL-6, IL-9, IP-10, PDGF-bb at week 24 (p<0,05). The serum levels of IL-10, IFN-γ increased at week 24 (p<0,05). In switching group MTX induced reduction in IL-6, IL-1Pa, IP-10 at week 12 (p<0,05). ADA induced significant reduction in proinflammatory (IL-12), anti-inflammatory (IL-9) cytokines, chemokines (IP-10, MCP-1, MIP-1β) and growth factors (VEGF), and increased in IL-10 and IFN-γ (week 12 of treatment) (Fig. 1) Figure 1 Conclusions Clinical efficacy of SC MTX therapy is associated with reduced of proinflammatory cytokines, chemokines and growth factors at weeks 12-24 of therapy. ADA therapy is characterized by a decrease in disease activity and reduction chemokine type cytokines in pts with early RA Disclosure of Interest : None declared DOI 10.1136/annrheumdis-2014-eular.2698</description><identifier>ISSN: 0003-4967</identifier><identifier>EISSN: 1468-2060</identifier><identifier>DOI: 10.1136/annrheumdis-2014-eular.2698</identifier><identifier>CODEN: ARDIAO</identifier><language>eng</language><publisher>London: BMJ Publishing Group LTD</publisher><ispartof>Annals of the rheumatic diseases, 2014-06, Vol.73 (Suppl 2), p.215-216</ispartof><rights>2014, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><rights>Copyright: 2014 (c) 2014, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttp://ard.bmj.com/content/73/Suppl_2/215.2.full.pdf$$EPDF$$P50$$Gbmj$$H</linktopdf><linktohtml>$$Uhttp://ard.bmj.com/content/73/Suppl_2/215.2.full$$EHTML$$P50$$Gbmj$$H</linktohtml><link.rule.ids>114,115,314,780,784,3196,23571,27924,27925,77600,77631</link.rule.ids></links><search><creatorcontrib>Avdeeva, A.S.</creatorcontrib><creatorcontrib>Novikov, A.A.</creatorcontrib><creatorcontrib>Aleksandrova, E.N.</creatorcontrib><creatorcontrib>Karateev, D.E.</creatorcontrib><creatorcontrib>Luchihina, E.L.</creatorcontrib><creatorcontrib>Nasonov, E.L.</creatorcontrib><title>THU0110 The Effect of Subcutaneous (SC) Methotrexate (MTX) and Adalimumab (ADA) on Cytokine Profile in MTX-Naive Patients with Early Rheumatoid Arthritis (RA)</title><title>Annals of the rheumatic diseases</title><description>Objectives To evaluate the changes in cytokine profile in MTX-naive patients (pts) with early RA during MTX and ADA+MTX therapy Methods Serum samples from 45 MTX-naive adults with early RA who received MTX (35 woman, mean age 53,5; 46-59,5 years, mean disease duration 7,0; 4,0-11,5 months, mean DAS 28 5,8; 4,9-6,4, RF positive-91%, anti-CCP positive-96%) were analyzed for selected markers of inflammation. The levels of IL-1b, IL-1Pa, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12, IL-13, IL-15, IL-17, Eotaxin, FGF-basic, IFN-γ, IP-10, MCP-1, MIP-1α, MIP-1β, RANTES, TNF-α, VEGF (pg/ml) were tested by multiplex technology xMAP at baseline and weeks 12 and 24 Results After 3 months the efficacy of SC MTX have met the goal (EULAR response) in 23 (51%) of pts (not switching group). Switching to combination with ADA was required in 22 (49%) of pts (switching group). The relations between achievement of LDA or remission according to treatment regimens are shown in the table 1. Table 1 Weeks Parameters Not switching group (n=23) Switching group (n=22) Baseline DAS 28 4,9 (4,3–6,0) 6,1 (5,9–6,8)§ Week 12 DAS 28 3,5 (2,8–3,9)* 5,3 (5,6–5,9)*§ DAS 28 remission/LDA 34,8% 0 Week 24 DAS 28 2,9 (2,1–3,6)* 3,4 (3,2–4,4)* DAS 28 remission/LDA 60,9% 31,8% *p<0,05 from baseline, §p<0,05 between the groups. In not-switching group MTX induced reduction in proinflammatory (IL-6, -17, TNF-α), anti-inflammatory (IL-4, -5, -9, -13) cytokines, chemokines (IP-10) and growth factors (FGF) at week 12; IL-6, IL-9, IP-10, PDGF-bb at week 24 (p<0,05). The serum levels of IL-10, IFN-γ increased at week 24 (p<0,05). In switching group MTX induced reduction in IL-6, IL-1Pa, IP-10 at week 12 (p<0,05). ADA induced significant reduction in proinflammatory (IL-12), anti-inflammatory (IL-9) cytokines, chemokines (IP-10, MCP-1, MIP-1β) and growth factors (VEGF), and increased in IL-10 and IFN-γ (week 12 of treatment) (Fig. 1) Figure 1 Conclusions Clinical efficacy of SC MTX therapy is associated with reduced of proinflammatory cytokines, chemokines and growth factors at weeks 12-24 of therapy. ADA therapy is characterized by a decrease in disease activity and reduction chemokine type cytokines in pts with early RA Disclosure of Interest : None declared DOI 10.1136/annrheumdis-2014-eular.2698</description><issn>0003-4967</issn><issn>1468-2060</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqVkcFuEzEQhi0EEqHwDpZ6SQ5b7HXi3YjTKqQUqQXUphI3a3Y91jrs2sX2Arlx4T14Np4Eh3DgijTSaEbz_79GHyHnnF1wLuRLcC70OI3axqJkfFngNEC4KOW6fkRmfCnrvJbsMZkxxkSxXMvqKXkW4z6PrOb1jPzcXd0zztmv7z92PdKtMdgl6g29m9puSuDQT5HO7zYLeoOp9yngN0hI5ze7jwsKTtNGw2DHaYSWzpvXzYJ6RzeH5D9Zh_RD8MYOSK2jWVC8A_slLyFZdCnSrzb1dAthONDb4xuQvM2GIfXBJptjb5vFc_LEwBDxxd9-Ru4vt7vNVXH9_s3bTXNdtLysWMGl7sRKrFCKtqwMCF3VjGstTV3pVQnIOhBGd21lsOwEyDVKzQA7061A5Doj5yffh-A_TxiT2vspuBypeFVV61xLlq9ena664GMMaNRDsCOEg-JMHZGof5CoIxL1B4k6IslqeVK34_6_hL8BddGYkA</recordid><startdate>201406</startdate><enddate>201406</enddate><creator>Avdeeva, A.S.</creator><creator>Novikov, A.A.</creator><creator>Aleksandrova, E.N.</creator><creator>Karateev, D.E.</creator><creator>Luchihina, E.L.</creator><creator>Nasonov, E.L.</creator><general>BMJ Publishing Group LTD</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope></search><sort><creationdate>201406</creationdate><title>THU0110 The Effect of Subcutaneous (SC) Methotrexate (MTX) and Adalimumab (ADA) on Cytokine Profile in MTX-Naive Patients with Early Rheumatoid Arthritis (RA)</title><author>Avdeeva, A.S. ; Novikov, A.A. ; Aleksandrova, E.N. ; Karateev, D.E. ; Luchihina, E.L. ; Nasonov, E.L.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b1270-16dc3535e63b27fa3d7801dd6f87d52ae0ca3fdcb7fe2c3a69e6d0aecfc5a35a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Avdeeva, A.S.</creatorcontrib><creatorcontrib>Novikov, A.A.</creatorcontrib><creatorcontrib>Aleksandrova, E.N.</creatorcontrib><creatorcontrib>Karateev, D.E.</creatorcontrib><creatorcontrib>Luchihina, E.L.</creatorcontrib><creatorcontrib>Nasonov, E.L.</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><jtitle>Annals of the rheumatic diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Avdeeva, A.S.</au><au>Novikov, A.A.</au><au>Aleksandrova, E.N.</au><au>Karateev, D.E.</au><au>Luchihina, E.L.</au><au>Nasonov, E.L.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>THU0110 The Effect of Subcutaneous (SC) Methotrexate (MTX) and Adalimumab (ADA) on Cytokine Profile in MTX-Naive Patients with Early Rheumatoid Arthritis (RA)</atitle><jtitle>Annals of the rheumatic diseases</jtitle><date>2014-06</date><risdate>2014</risdate><volume>73</volume><issue>Suppl 2</issue><spage>215</spage><epage>216</epage><pages>215-216</pages><issn>0003-4967</issn><eissn>1468-2060</eissn><coden>ARDIAO</coden><abstract>Objectives To evaluate the changes in cytokine profile in MTX-naive patients (pts) with early RA during MTX and ADA+MTX therapy Methods Serum samples from 45 MTX-naive adults with early RA who received MTX (35 woman, mean age 53,5; 46-59,5 years, mean disease duration 7,0; 4,0-11,5 months, mean DAS 28 5,8; 4,9-6,4, RF positive-91%, anti-CCP positive-96%) were analyzed for selected markers of inflammation. The levels of IL-1b, IL-1Pa, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12, IL-13, IL-15, IL-17, Eotaxin, FGF-basic, IFN-γ, IP-10, MCP-1, MIP-1α, MIP-1β, RANTES, TNF-α, VEGF (pg/ml) were tested by multiplex technology xMAP at baseline and weeks 12 and 24 Results After 3 months the efficacy of SC MTX have met the goal (EULAR response) in 23 (51%) of pts (not switching group). Switching to combination with ADA was required in 22 (49%) of pts (switching group). The relations between achievement of LDA or remission according to treatment regimens are shown in the table 1. Table 1 Weeks Parameters Not switching group (n=23) Switching group (n=22) Baseline DAS 28 4,9 (4,3–6,0) 6,1 (5,9–6,8)§ Week 12 DAS 28 3,5 (2,8–3,9)* 5,3 (5,6–5,9)*§ DAS 28 remission/LDA 34,8% 0 Week 24 DAS 28 2,9 (2,1–3,6)* 3,4 (3,2–4,4)* DAS 28 remission/LDA 60,9% 31,8% *p<0,05 from baseline, §p<0,05 between the groups. In not-switching group MTX induced reduction in proinflammatory (IL-6, -17, TNF-α), anti-inflammatory (IL-4, -5, -9, -13) cytokines, chemokines (IP-10) and growth factors (FGF) at week 12; IL-6, IL-9, IP-10, PDGF-bb at week 24 (p<0,05). The serum levels of IL-10, IFN-γ increased at week 24 (p<0,05). In switching group MTX induced reduction in IL-6, IL-1Pa, IP-10 at week 12 (p<0,05). ADA induced significant reduction in proinflammatory (IL-12), anti-inflammatory (IL-9) cytokines, chemokines (IP-10, MCP-1, MIP-1β) and growth factors (VEGF), and increased in IL-10 and IFN-γ (week 12 of treatment) (Fig. 1) Figure 1 Conclusions Clinical efficacy of SC MTX therapy is associated with reduced of proinflammatory cytokines, chemokines and growth factors at weeks 12-24 of therapy. ADA therapy is characterized by a decrease in disease activity and reduction chemokine type cytokines in pts with early RA Disclosure of Interest : None declared DOI 10.1136/annrheumdis-2014-eular.2698</abstract><cop>London</cop><pub>BMJ Publishing Group LTD</pub><doi>10.1136/annrheumdis-2014-eular.2698</doi><tpages>2</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0003-4967 |
| ispartof | Annals of the rheumatic diseases, 2014-06, Vol.73 (Suppl 2), p.215-216 |
| issn | 0003-4967 1468-2060 |
| language | eng |
| recordid | cdi_proquest_journals_1777977940 |
| source | BMJ Journals - NESLi2 |
| title | THU0110 The Effect of Subcutaneous (SC) Methotrexate (MTX) and Adalimumab (ADA) on Cytokine Profile in MTX-Naive Patients with Early Rheumatoid Arthritis (RA) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T17%3A30%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=THU0110%E2%80%85The%20Effect%20of%20Subcutaneous%20(SC)%20Methotrexate%20(MTX)%20and%20Adalimumab%20(ADA)%20on%20Cytokine%20Profile%20in%20MTX-Naive%20Patients%20with%20Early%20Rheumatoid%20Arthritis%20(RA)&rft.jtitle=Annals%20of%20the%20rheumatic%20diseases&rft.au=Avdeeva,%20A.S.&rft.date=2014-06&rft.volume=73&rft.issue=Suppl%202&rft.spage=215&rft.epage=216&rft.pages=215-216&rft.issn=0003-4967&rft.eissn=1468-2060&rft.coden=ARDIAO&rft_id=info:doi/10.1136/annrheumdis-2014-eular.2698&rft_dat=%3Cproquest_cross%3E4008700231%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1777977940&rft_id=info:pmid/&rfr_iscdi=true |